The first half of 2026 closed with an important regulatory development for the chemical industry: the expiration of the Toxic Substances Control Act (TSCA) fee authority. While ongoing regulatory activities continue, the absence of renewed congressional authorization has created uncertainty for companies introducing new chemical substances or managing products under active EPA review.
For pharmaceutical manufacturers, chemical suppliers, and regulatory affairs teams, the situation extends beyond policy discussions. Delays in fee collection authority and potential impacts on review timelines may influence product commercialization, procurement schedules, and investment planning throughout H2 2026. Organizations relying on timely regulatory approvals should remain proactive while preparing for possible administrative delays.
Understanding the TSCA Fee Authority
The Toxic Substances Control Act provides the regulatory framework for reviewing industrial chemicals entering the U.S. market.
The fee authority supports regulatory activities such as:
New chemical reviews
Risk evaluations
Administrative processing
Scientific assessments
Compliance monitoring
Regulatory oversight
Without renewed authorization, uncertainty may arise regarding funding mechanisms for future review activities.
Regulatory Planning Is Becoming More Important
Although existing regulatory processes continue, companies should prepare for potential scheduling adjustments.
Important planning considerations include:
Longer review timelines
Additional regulatory monitoring
Earlier submission planning
Internal compliance reviews
Documentation readiness
Communication with regulatory consultants
Advance preparation can reduce business disruptions if approval timelines extend.
PP Homopolymer 105G (Injection) - Vietnam CAS: 9003-07-0
Pharmaceutical Manufacturers Should Review Development Pipelines
Companies developing new pharmaceutical products or manufacturing materials should evaluate how regulatory timing may affect commercial plans.
Areas requiring attention include:
New excipients
Specialty intermediates
Process chemicals
Novel formulations
Manufacturing technologies
Supporting documentation
Integrating regulatory planning into product development helps minimize future delays.
Supplier Documentation Supports Regulatory Compliance
Reliable supplier documentation remains essential throughout pharmaceutical manufacturing.
Key documents include:
Certificates of Analysis
Technical Data Sheets
Safety Data Sheets
GMP certifications
Batch traceability
Regulatory declarations
Maintaining complete documentation simplifies future regulatory submissions and quality audits.
Procurement Teams Should Continue Business as Usual
Despite legislative uncertainty, procurement departments should avoid delaying critical purchasing decisions.
Recommended practices include:
Continue scheduled procurement.
Maintain approved supplier lists.
Monitor regulatory developments.
Strengthen supplier communication.
Preserve quality documentation.
Review long-term contracts.
Stable procurement practices help maintain production continuity regardless of regulatory developments.
Cross-Functional Collaboration Reduces Risk
Effective regulatory management requires coordination across multiple business functions.
Departments that should collaborate include:
Regulatory Affairs
Procurement
Quality Assurance
Manufacturing
Supply Chain
Research & Development
Early communication enables organizations to respond more effectively to changing regulatory conditions.
Monitoring Legislative Developments Will Remain Essential
Throughout H2 2026, companies should continue monitoring government announcements affecting chemical regulation.
Organizations should track:
Congressional activity
EPA guidance
Industry association updates
Regulatory consultations
Compliance deadlines
Policy implementation timelines
Regular monitoring allows companies to adjust planning before regulatory changes take effect.
Procurement Priorities for H2 2026
Pharmaceutical and specialty chemical companies should strengthen regulatory readiness while maintaining supply continuity.
Recommended actions include:
Continue planned regulatory submissions.
Maintain supplier qualification programs.
Prepare for possible review delays.
Strengthen compliance documentation.
Monitor legislative progress.
Review product approval timelines.
A proactive approach will help organizations navigate uncertainty while supporting uninterrupted business operations.
Market Outlook
The expiration of TSCA fee authority introduces a temporary period of regulatory uncertainty, but it does not fundamentally alter the long-term outlook for pharmaceutical and specialty chemical markets. Most manufacturers are expected to continue planned investments, procurement activities, and product development while awaiting legislative clarity.
For H2 2026, companies that maintain strong compliance programs, monitor regulatory developments closely, and integrate regulatory planning into procurement and product development strategies will be better positioned to manage potential approval delays and maintain competitive advantage.
Key Takeaways
TSCA fee authority expiration creates temporary regulatory uncertainty.
Pharmaceutical companies should continue planned procurement activities.
Regulatory planning should be integrated into product development.
Supplier documentation remains essential for compliance.
Cross-functional collaboration improves regulatory readiness.
Legislative monitoring will remain important throughout H2 2026.
Proactive planning helps minimize approval and commercialization risks.
Strong compliance systems support long-term business continuity.
